Foundation Medicine
Foundation Medicine, Sumitomo Pharma to Develop CDx for Acute Leukemia Treatment
The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
In Brief This Week: Mount Sinai, AAVantgarde Bio, Lantern Pharma, Exegenesis Bio, AlveoGene
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Merus Nabs FDA Accelerated Approval for Bizengri in NRG1 Fusion-Positive NSCLC, Pancreatic Cancer
The approval is based on overall response rates from the Phase II eNRGy study, which enrolled advanced, previously treated NRG1 fusion-positive patients.
Jul 24, 2024